Ann: AVL Launches Underwritten Share Purchase Plan, page-69

First 69 Last

Share
Profile

Follow
Wayno14

645 Posts.

82

27/08/19

18:40

Post #: 40180740
Share

Originally posted by red-frog: ↑

AVL have yet to seek costings from fabrication companies which will be required to finalise the dfs. Detailed engineering design and costings will be handled by an independent expert company once the large scale pilot testing has been completed.

TMT used Wave International to organise the engineering design and costing. Quotes were sought about 3 months ago from local fabrication companies, so we will need to see the pilot testing results soon if the AVL dfs is to be released by the end of this year.

TMT have employed Dave English as Project Director. He’s about as good as they come. He oversaw IGO’s Nova Nickel Project from pfs through to construction and commissioning, SFR’s Degrussa Project and later on the Mt Holland Earl Grey Project, as well as Windamurra. He is known as a doer which is exactly what we need here.

Time for AVL to get moving and ensure they hit their timelines which has been very poor to date.

Project funding is virtually non existent for just about all companies at the moment, so I can’t see AVL having much chance of getting theirs before the dfs is completed. It seems very optimistic to think we can organise funding without knowing just what the capex and opex will be.

TMT have given themselves the best possible chance of securing project funding if the general market conditions improve, now AVL has to get to the same stage.

I think AVL is doing everything properly including the large 30t sampling program to give themselves an edge in the quality of the dfs, but the market won’t really care if all they see is missed timelines and extra costs. It may pay off long term if they release a very comprehensive dfs and are then also just waiting for funding opportunities to present themselves.

TMT are waiting at the starting line and AVL are still putting their shoes on, but as TMT holders have witnessed, the market is showing very little interest in the dfs. Only funding counts at the end of the day.

Hopefully both companies can eventually get their projects funded once the trade war between China and USA gets sorted out. Until then the headwinds are strong.

Expand

Bugger the headwinds l want tailwinds!

AVL Price at posting: 1.1¢ Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 39 more messages in this thread...

First 69 Last

Add AVL (ASX) to my watchlist

(20min delay)
Last 1.6¢		Change 0.000(0.00%)		Mkt cap ! $138.1M

Open	High	Low	Value	Volume
1.5¢	1.6¢	1.5¢	$86.22K	5.449M

Buyers (Bids)

No.	Vol.	Price($)
42	10699611	1.5¢

Sellers (Offers)

Price($)	Vol.	No.
1.6¢	6185675	17

View Market Depth

No.	Vol.	Price($)
41	10632945	0.015
71	51493879	0.014
27	8416509	0.013
23	8434581	0.012
10	1936480	0.011

Price($)	Vol.	No.
0.016	6185675	17
0.017	6904284	27
0.018	3934118	14
0.019	4820062	8
0.020	7609194	19

Last trade - 16.10pm 07/10/2024 (20 minute delay)

AVL (ASX) Chart

Ann: AVL Launches Underwritten Share Purchase Plan, page-69

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: AVL Launches Underwritten Share Purchase Plan, page-69

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News